San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
Using X-rays and neutron beams, a team of researchers from the University of California, San Diego School of Medicine, University of Utah and Oak Ridge National Laboratory have teased out new information about Protein Kinase A (PKA), a ubiquitous master switch that helps regulate fundamental cellular functions like energy consumption and interactions with hormones, neurotransmitters and drugs.
With supplies of ZMapp exhausted, another drug from San Diego is being used against Ebola.
SAN DIEGO, Oct. 9, 2014 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced an oral presentation on the pharmacology of PEGPH20 at the New York Academy of Sciences symposium “Targeting Key Vulnerabilities in Pancreatic Cancer,” being held on October 9, 2014 in New York City. The presentation includes preclinical data showing that treatment with PEGPH20 of tumors with high levels of hyaluronan (HA) is associated with alterations of the tumor microenvironment resulting in a reduction of fluid pressure and an increase of blood flow inside the tumors. These changes allow anti-cancer therapies such as chemotherapies, monoclonal antibodies and activated immune cells to have greater access into the tumors. The presentation will also include data showing that in selected animal models, treatment with PEGPH20 plus anti-cancer therapies resulted in longer survival and reduced metastases compared to anti-cancer therapies alone.
PEGPH20, an investigational PEGylated form of rHuPH20 under development by Halozyme, degrades the hyaluronan in the tumor microenvironment that may provide a supportive environment in many solid tumors.
“These data in animal models support our ongoing Phase 2 clinical trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer and offer scientific insight into ways to utilize PEGPH20 to favorably alter the tumor stroma of HA rich tumors to potentially improve many cancer therapies,” stated H. Michael Shepard, Ph.D., Vice President and Chief Scientific Officer.
Title: “Enzymatic Remodeling of the Pancreatic Ductal Adenocarcinoma Tumor Microenvironment to Improve Chemotherapeutic Efficacy”Presentation Time: 3:45 p.m. ET/12:45 p.m. PT.Summary: Pancreatic ductal adenocarcinoma (PDA) is characterized by a tumor microenvironment (TME) with high stromal desmoplasia, a reduction in vessel density, and poor perfusion, all instrumental in PDAs’ observed resistance to chemotherapeutic intervention. Hyaluronan (HA) has been shown to accumulate to high levels in approximately 90% of PDA tumors, and is thought to be a key component of this desmoplastic response. In preclinical mouse models, including tumor xenografts, patient-derived tumor xenografts, and genetically engineered mouse models of pancreatic cancer (KPC), depletion of HA from the TME with a pegylated recombinant human hyaluronidase PH20 (PEGPH20) is associated with remodeling of the tumor stroma, reduction of tumor interstitial fluid pressure, expansion of tumor blood vessels and facilitated delivery of chemotherapy. Studies in the KPC model have shown that increased tumor perfusion following PEGPH20 treatment in combination with gemcitabine persists for weeks after therapy cessation. Combinations with nab-paclitaxel and gemcitabine more than doubles survival in some pancreatic tumor models.
About HalozymeHalozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company’s research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme’s pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning future actions relating to the development of PEGPH20 including the possibility that PEGPH20 may be used to address pancreatic cancer) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including delays in completion of clinical trials and other development activities, the possibility of safety events, unexpected expenditures and costs, unexpected results or delays in regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2014.
Investor Contact:Schond GreenwayHalozyme Therapeutics858firstname.lastname@example.org
Media Contact:Susan Neath Francis212email@example.com
Logo – http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
SOURCE Halozyme Therapeutics, Inc.
President Obama’s BRAIN Initiative, a federal research effort designed to help researchers answer fundamental questions about how the brain works, has in recent months awarded scientists at UC San Diego with more than $10 million in grants, cementing the campus’s reputation as one of the world’s top centers for neuroscience research.
Strand Life Sciences To Demonstrate New Strand NGS Features At 2014 American Society of Human Genetics Conference
SAN FRANCISCO, Oct. 9, 2014 /PRNewswire/ — Strand Life Sciences (Strand) representatives will demonstrate new capabilities of the company’s next-generation sequencing data software, Strand NGS at the 64th Annual Meeting of The American Society of Human Genetics (ASHG) to be held from Oct. 18th to 22nd in San Diego, California. The meeting will feature invited presentations by the world’s leading geneticists, workshops and sessions about new developments in basic, translational, and clinical human genetics research and technology. At ASHG, Strand will highlight new features in Strand NGS such as the enhanced SNP and copy number detection workflows and multi-omic analyses.
The Strand NGS 2.1 release introduces custom SNP filters in the SNP detection workflow to filter out potentially false positive variants. It also provides the ability to create coverage profiles that store the basic coverage statistics for each target region of interest, a benefit to Copy Number Variation (CNV) workflows. “These profiles can be readily used in the CNV workflow as a reference to detect copy number variations. These enhancements reflect Strand’s continued commitment to develop new and better methods for NGS data analysis,” says Dr. Rohit Gupta, Head, NGS Application Science, Strand.
“I have used Strand NGS for more than two years and have seen it significantly increase my lab’s productivity. From small RNA-Seq, ChIP-Seq, and targeted RNA-Seq, through whole-transcriptome, whole-methylome, and even whole-genome analyses, there are so many features, workflows and tools available that it literally takes the work out of NGS analysis. There is no other NGS analysis product, commercial or otherwise, that can do so many things this well, and they are continually adding more features in response to customer needs. I can’t think of a better option for the biologist who wants to quickly and comprehensively analyze and understand their NGS data,” says Frank A. Middleton, Associate Professor and Director, SUNY Upstate Medical University.
Strand NGS is developed on Strand’s proprietary ‘Avadis®’ framework which powers high-throughput data analysis solutions used by more than 3,000 customers worldwide including top pharmaceutical companies, biotechnology organizations, research and academic institutions in over 40 countries. An enterprise version of Strand NGS (Server Edition) is also available and it allows multi-member teams to collaborate, share data, and speed up the analysis. At ASHG 2014, Strand will present five posters in the sessions on ‘Bioinformatics and Genomic Technology’ and ‘Clinical Genetic Testing’. The posters highlight benchmarking studies and case studies performed at Strand. A schedule of these poster sessions is available on the Strand NGS website. Come meet Strand experts for a demonstration of the new Strand NGS features at ASHG Booth #338.
About Strand Life SciencesFounded in 2000, Strand is a leader in technology innovations for healthcare using genomics. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world.
For more information, visit www.strandls.com or follow us on twitter: @StrandLife
SOURCE Strand Life Sciences
William E. Moerner, one of three scientists who this week were named winners of the 2014 Nobel Prize in Chemistry, first applied his Nobel Prize-winning discovery to biological problems while working in the basement of Urey Hall as a professor of chemistry and biochemistry at UC San Diego from 1995 to 1998.
A team of scientists around Sanford-Burnham’s Ranjan Perera, Ph.D., has identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients, but not in normal healthy individuals. The study sets the stage for the development of more-sensitive and specific non-invasive tests for prostate cancer than those currently available
LA JOLLA–Scientists at the Salk Institute and Beth Israel Deaconess Medical Center (BIDMC) in Boston have discovered a new class of molecules–produced in human and mouse fat–that protects against diabetes.
The survivin protein may be a new therapeutic target for brain cancer
MOUNTAIN VIEW, Calif., Oct. 8, 2014 /PRNewswire/ — The solutions to today’s most pressing medical issues, the creation of tomorrow’s next generation technologies, and the inventions of our future healthcare system will be presented and debated at the fifth-ever Exponential Medicine conference, a four-day event at the Hotel del Coronado in San Diego, CA, November 9-12, 2014.
Bringing together inventors, entrepreneurs, academics and creative intellectuals, Exponential Medicine, hosted by Singularity University, will address major medical challenges to transform and shape the next generation of healthcare.
Topics such as personalized stem cell lines, artificial intelligence, point-of-care lab-on-a-chip diagnostics, large-scale bioinformatics, 3D printing, synthetic biology, and the implications of low-cost genomics will be explored, along with their benefit to the healthcare system. These technologies will also be examined in the context of the current explosions of digital information, “big” data, and our new world of connected and distributed healthcare.
The preliminary 2014 conference program is available at: http://ExponentialMedicine.com/Schedule
Throughout the four-day conference, world-class faculty will engage with carefully curated, cross-disciplinary participants through a mix of talks, workshops, demo sessions, and startup competitions. Noted speakers include Craig Venter, PhD, Founder, J. Craig Venter Institute, CEO, Human Longevity Inc.; Daniel Kraft, MD, Founding Executive Director and Chair, Exponential Medicine and Faculty Chair for Medicine, Singularity University; and Peter Diamandis, MD, Co-founder & Executive Chairman of Singularity University and Chairman and CEO of the XPRIZE Foundation. Additional faculty members are highlighted below:
Laura Esserman, MD: Director, UCSF Carol Franc Buck Breast Care Center
Cigall Kadoch, PhD: Assistant Professor, Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School
Isaac Kohane, MD: Co-Director, Center for Biomedical Informatics at Harvard Medical School
Marty Kohn, MD: Chief Medical Scientist, Jointly Health; Chief Medical Scientist, IBM
Ray Kurzweil: Director of Engineering at Google, Co-founder & Chancellor of Singularity University, Inventor, Futurist, Author
John Mattison, MD: Chief Medical Information Officer, Kaiser-Permanente
Catherine Mohr, MD: Director of Medical Research, Intuitive Surgical
Jeffrey Olgin, MD: Chief, Division of Cardiology Co-Director, Heart and Vascular Center UCSF. Director, Health eHeart Study
Alan Russell, PhD: Director, Disruptive Health Technology Institute at Carnegie Mellon University, Founding Director, McGowan Institute for Regenerative Medicine at the University of Pittsburgh
Evan Snyder, MD, PhD: Professor and Program Director of Stem Cells and Regenerative Medicine at the Burnham Institute for Medical Research
Tony Young, MBBS, PhD: Director of Medical Innovation, National Health Service (NHS), EnglandTo see the full faculty list, please visit: http://exponential.singularityu.org/medicine/november-2014-faculty/
Media are invited to be a part of this event. If interested, please register below: http://ExponentialMedicine.com/press.
Additionally, space is still available for those interested in participating as an attendee. Apply at: http://ExponentialMedicine.com/Apply.
Date: November 9-12, 2014
Location: Hotel del Coronado1500 Orange Ave Coronado, CA 92118
Follow us on Twitter: @exponentialmed and #xmed
About Singularity University Singularity University (SU) is a benefit corporation headquartered at NASA Research Park in Silicon Valley. SU provides educational programs, innovative partnerships and a business accelerator to help individuals, businesses, institutions, investors, NGOs and governments understand cutting-edge technologies and how to utilize these technologies to positively impact billions of people. From our inception in 2008, SU has empowered individuals from more than 85 countries to apply exponentially growing technologies to address humanity’s grand challenges. SU’s Founding Corporate Partners include Genentech, Autodesk, Cisco, ePlanet Ventures, Google, Kauffman Foundation and Nokia. To learn more, visit singularityu.org.
SOURCE Singularity University